<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690817</url>
  </required_header>
  <id_info>
    <org_study_id>16/42/426</org_study_id>
    <nct_id>NCT03690817</nct_id>
  </id_info>
  <brief_title>Hearing Loss, Vestibular Loss and Cognitive Performance</brief_title>
  <official_title>The Link Between Hearing Loss, Vestibular Loss and Cognitive Performance: Cross-sectional Data in Patients With Bilateral Vestibulopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hearing loss is an established independent risk factor for dementia. Likewise, recent&#xD;
      research demonstrated cognitive deficits in subjects with vestibular loss. However, in these&#xD;
      studies data have not been adjusted for the hearing status of the enrolled study subjects. As&#xD;
      hearing loss prevalence is high in patients with vestibular loss, this could be a major&#xD;
      confounder. Therefore, in this study the investigators investigate cognition in patients with&#xD;
      bilateral vestibulopathy with and without hearing loss. The investigators adjust data for the&#xD;
      hearing status of the patients to explore the link between hearing loss, vestibular loss and&#xD;
      cognition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Repeatable Battery for the Assessment of Neuropsychological Status for Hearing Impaired Individuals (RBANS-H): total score</measure>
    <time_frame>2 years</time_frame>
    <description>General cognitive assessment, cfr. Claes et al 2016. The total-score is standardized with a mean of 100 and a standard deviation of 15. The higher the total score, the better the cognition of the participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virtual Morris Water Maze performance</measure>
    <time_frame>2 years</time_frame>
    <description>Spatial cognition assessment, cfr. Hamilton. Path length and latency are recorded, the higher the worse the spatial cognition of the participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Repeatable Battery for the Assessment of Neuropsychological Status for Hearing Impaired Individuals (RBANS-H): index scores</measure>
    <time_frame>2 years</time_frame>
    <description>Cfr. Claes et al 2016. The subscale are standardized with a mean of 100 and standard deviation of 15. The higher the score, the better the performance on a specific subdomain of cognition (attention, immediate memory, delayed memory, visuospatial and language)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Vestibular Disorder</condition>
  <arm_group>
    <arm_group_label>Bilateral vestibulopathy</arm_group_label>
    <description>Patients with bilateral vestibulopathy, according to the Barany Criteria (2017, Strupp).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Subjects without vestibular or neurological diseases (DHI&lt;5), and with normal hearing thresholds according to their age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>RBANS-H, virtual Morris Water Maze</intervention_name>
    <description>Cognitive tasks for respectively: general cognition and spatial cognition</description>
    <arm_group_label>Bilateral vestibulopathy</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bilateral vestibulopathy, which was confirmed by vestibular testing, were&#xD;
        enrolled in the patient group. Healthy controls with normal hearing and vestibular system&#xD;
        were used to compare cognitive outcome measures with. Correction were made for age, sex,&#xD;
        education and computer usage.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria for BVP patients were:&#xD;
&#xD;
          1. Bilaterally reduced vestibular function, as defined by the Bárány Criteria for BVP&#xD;
             (Michael Strupp 2017):&#xD;
&#xD;
               -  horizontal angular VOR gain &lt; 0.6 measured by the vHIT, and/or&#xD;
&#xD;
               -  reduced caloric response (sum of bithermal, 30° and 44°, max. peak slow phase&#xD;
                  velocity (SPV) on each side &lt; 6°/sec), and/or&#xD;
&#xD;
               -  reduced horizontal angular VOR gain &lt; 0.1 upon sinusoidal stimulation on a&#xD;
                  rotatory chair. At our clinic rotatory chair tests are performed using sinusoidal&#xD;
                  rotation (0.05 Hertz) with a peak velocity of 60°/sec (Van der Stappen A 2000).&#xD;
&#xD;
          2. Disease duration of BVP &gt; 6 months.&#xD;
&#xD;
        Healthy controls (HC). Only subjects with no history of vertigo, scores &lt;5 on the Dizziness&#xD;
        Handicap Inventory (DHI) and normal hearing thresholds at 0.25 - 8 kHz, based on age and&#xD;
        sex (defined by the BS 6951:1988, EN 27029:1991 and ISO 7029-1984 standards), were enrolled&#xD;
        in the study.&#xD;
&#xD;
        For both BVP patients and HC the following additional inclusion criteria were applied: 1)&#xD;
        Age ≥ 18 years; 2) Fluency in Dutch; 3) No history of neurological diseases (e.g. dementia,&#xD;
        Parkinson's disease, cerebrovascular accident, etc.); 4) Absence of clinical signs&#xD;
        indicating dementia or mild cognitive impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bieke Dobbels, MD</last_name>
    <phone>0032 3 821 34 51</phone>
    <email>biekedobbels@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Van de Heyning, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Van Rompaey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Griet Mertens, Ausc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Moyaert, Ausc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Ethisch Comité, UZA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Vestibular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

